Neutralization of the infectivity of sporozoites of Plasmodium knowlesi by antibodies to a synthetic peptide
about
Advances and challenges in malaria vaccine developmentImmunological mechanisms underlying protection mediated by RTS,S: a review of the available data.Presentation of T-cell epitopes assembled as multiple-antigen peptides to murine and human T lymphocytes.An unstable Th epitope of P. falciparum fosters central memory T cells and anti-CS antibody responses.Preclinical vaccine study of Plasmodium vivax circumsporozoite protein derived-synthetic polypeptides formulated in montanide ISA 720 and montanide ISA 51 adjuvants.Memory B-cell and antibody responses induced by Plasmodium falciparum sporozoite immunization.Circumsporozoite protein of Plasmodium berghei: gene cloning and identification of the immunodominant epitopes.Rabbit and human antibodies to a repeated amino acid sequence of a Plasmodium falciparum antigen, Pf 155, react with the native protein and inhibit merozoite invasion.Expression in yeast of a Plasmodium vivax antigen of potential use in a human malaria vaccineEnhanced epitopic response to a synthetic human malarial peptide by preimmunization with tetanus toxoid carrierInduction of biologically active antibodies by a polyvalent synthetic vaccine constructed without carrierAntibodies to pre-erythrocytic Plasmodium falciparum antigens and risk of clinical malaria in Kenyan children.Biologically active antibodies elicited by a synthetic circumsporozoite peptide of Plasmodium knowlesi administered in saline with a muramyl dipeptide derivativeHuman-human hybridomas secreting monoclonal antibodies to the Mr 195,000 Plasmodium falciparum blood stage antigen.Experimental vaccination of chicks with Plasmodium gallinaceum sporozoites. I. Circumsporozoite proteins are expressed by sporozoites recovered from both salivary glands and midguts of mosquitoes.
P2860
Q21032463-C9CB34C7-F2F5-4105-B2A6-C11ADAAE22A4Q33521372-2C705EF8-A923-484B-82C9-A107292F4F14Q33603399-ADCEECFE-31A7-41E6-9A2F-7DD770F67B40Q33830488-485C5E13-1422-4AFA-9ECE-9FA64698A42DQ34546208-45010103-9005-4E70-9128-850447974AD9Q34563555-67528AF9-7C9D-4146-99C6-41D528DEF07DQ35063553-EA8CB05D-8B9D-44E5-BC31-CEEC5DD3B2B8Q35590960-6AAFA83A-F49A-4CC3-8A74-F761FCBDE4A8Q36353517-9F2F8452-EBED-46B2-BE91-E477F598A30DQ37007738-5A12D192-483E-403E-B45C-82B336011597Q37020185-F6D25363-FF00-4E1B-B3EC-C24E63C4E41DQ37023939-17BABCFB-1386-4E13-8C09-9A12A756C994Q37034348-282C29C1-F87A-4A55-912B-2F90CC73279AQ42005028-6468DA52-259E-492E-836E-5CE49A772E23Q42993636-DC159C0B-77F2-4575-8E3D-DC8A4627EE6D
P2860
Neutralization of the infectivity of sporozoites of Plasmodium knowlesi by antibodies to a synthetic peptide
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年学术文章
@wuu
1984年学术文章
@zh-cn
1984年学术文章
@zh-hans
1984年学术文章
@zh-my
1984年学术文章
@zh-sg
1984年學術文章
@yue
1984年學術文章
@zh
1984年學術文章
@zh-hant
name
Neutralization of the infectiv ...... ibodies to a synthetic peptide
@ast
Neutralization of the infectiv ...... ibodies to a synthetic peptide
@en
type
label
Neutralization of the infectiv ...... ibodies to a synthetic peptide
@ast
Neutralization of the infectiv ...... ibodies to a synthetic peptide
@en
prefLabel
Neutralization of the infectiv ...... ibodies to a synthetic peptide
@ast
Neutralization of the infectiv ...... ibodies to a synthetic peptide
@en
P2093
P2860
P356
P1476
Neutralization of the infectiv ...... ibodies to a synthetic peptide
@en
P2093
D H Schlesinger
J Barnwell
V Nussenzweig
P2860
P304
P356
10.1084/JEM.160.3.935
P407
P577
1984-09-01T00:00:00Z